Table 1. Characteristics of eligible participants from the Cardiovascular Health Study.
Values are shown as frequencies and (%) unless otherwise indicated
| Total | European Americans | African Americans | |
|---|---|---|---|
| N | 2,234 | 1,934 | 300 |
| Mean follow-up per person, years | 8.7 | 8.9 | 7.3 |
| Number of incident PCa cases | 215 (9.6) | 175 (9.1) | 40 (13.3) |
| Age in years at baseline, mean ± SD | 73.3 ± 5.7 | 73.4 ± 5.7 | 72.7 ± 5.8 |
| 65-69 | 684 (30.6) | 579 (29.9) | 105 (35.0) |
| 70-74 | 748 (33.5) | 640 (33.1) | 108 (36.0) |
| 75-79 | 449 (20.1) | 403 (20.8) | 46 (15.3) |
| 80-84 | 251 (11.2) | 225 (11.6) | 26 (8.7) |
| ≥85 | 102 (4.6) | 87 (4.5) | 15 (5.0) |
| BMI (kg/m2), mean ± SD | 26.4 ± 3.8 | 26.4 ± 3.7 | 26.6 ± 4.3 |
| <25.0 | 808 (36.2) | 703 (36.4) | 105 (35.0) |
| 25.0-29.9 | 1,077 (48.2) | 937 (48.5) | 140 (46.7) |
| ≥30.0 | 341 (15.3) | 287 (14.8) | 54 (18.0) |
| Missing | 8 (0.4) | 7 (0.4) | 1 (0.3) |
| Clinic | |||
| NC (Bowman Gray) | 541 (24.2) | 445 (23.0) | 96 (32.0) |
| CA (Davis) | 584 (26.1) | 495 (25.6) | 89 (29.7) |
| MD (Hopkins) | 530 (23.7) | 526 (27.2) | 4 (1.3) |
| PA (Pittsburg) | 579 (25.9) | 468 (24.2) | 111 (37.0) |
| Smoking | |||
| Never | 716 (32.1) | 619 (32.0) | 97 (32.3) |
| Former | 1,273 (57.0) | 1,131 (58.5) | 142 (47.3) |
| Current | 242 (10.8) | 182 (9.4) | 60 (20.0) |
| Missing | 3 (0.1) | 2 (0.1) | 1 (0.3) |
| Physical activity, kcal/mo | 481 ± 534 | 508 ± 550 | 312 ± 372 |
| Median (IQR) | 309 (119-663) | 330 (132-703) | 197 (67-423) |
| Diabetes | 753 (33.7) | 645 (33.4) | 108 (36.0) |
| Missing | 11 (0.5) | 1 (0.1) | 10 (3.3) |
| Current NSAID use | 220 (9.9) | 188 (9.7) | 32 (10.7) |
| Alcohol, beverages/week | 3.8 ± 8.3 | 3.9 ± 8.1 | 3.4 ± 9.0 |
| Median (IQR) | 0.25 (0.0-3.0) | 0.25(0.0-3.0) | 0.0 (0.0-2.0) |
| CRP blood concentration (mg/l)1 | |||
| Median (IQR) | 2.4 (1.2-4.2) | 2.3 (1.2-4.1) | 3.0 (1.5-5.2) |
| Mean ± SE | 4.7 ± 8.8 | 4.6 ± 9.1 | 5.1 ± 6.8 |
| Range | 0.1-142.6 | 0.1-142.6 | 0.2-61.3 |
| ln(CRP), mean ± SE | 0.9 ± 1.1 | 0.9 ± 1.0 | 1.1 ± 1.0 |
| Missing | 20 (0.9) | 14 (0.7) | 6 (2.0) |
| CRP >10 mg/l | 229 (11.2) | 186 (10.3) | 43 (16.3) |
| IL-6 blood concentration (pg/ml)2 | |||
| Median (IQR) | 1.8 (1.3-2.7) | 1.8 (1.3-2.7) | 1.7 (1.2-2.8) |
| Mean ± SE | 2.3 ± 1.9 | 2.4 ± 1.9 | 2.2 ± 1.6 |
| Range | 0.3-23.6 | 0.3-23.6 | 0.4-12.1 |
| ln (IL6), mean ± SE | 0.7 ± 0.6 | 0.7 ± 0.6 | 0.6 ± 0.6 |
| Missing | 211 (9.4) | 184 (9.5) | 27 (9.0) |
| Stage of disease | |||
| Local | 114 (53.0) | 88 (50.3) | 26 (65.0) |
| Regional | 26 (12.1) | 20 (11.4) | 6 (15.0) |
| Distant | 11 (5.1) | 10 (5.7) | 1 (2.5) |
| Unknown | 64 (29.8) | 57 (32.6) | 7 (17.5) |
| Gleason score | |||
| 2-4 | 31 (14.4) | 25 (14.3) | 6 (15.0) |
| 5-7 | 113 (52.6) | 89 (50.9) | 24 (60.0) |
| 8-10 | 49 (22.8) | 39 (22.3) | 10 (25.0) |
| Unknown | 22 (10.2) | 22 (12.6) | 0 (0.0) |
1
Based on a total sample size of 2,214 (20 missing)
2
Based on a total sample size of 2,023 (211 missing)